Sun. Jul 21st, 2019

MediPharm Labs Enlarging Legal Team Enhancing Cannabis proficiency, participating at coming Conference

MediPharm Labs, an international frontrunner in dedicated extraction of cannabis, its distillation and purification, and cannabinoid isolation, is proud to publicize that is has extended its legal team with the recruitment of Daniel Overall (B. Comm, JD) as the Legal Director.

Moreover, the Company declared it’s partaking at the approaching conferences:

  • The BMO Capital Markets 2019 Cannabis Conference, April 4, 2019 (taking place in Toronto)
  • The GMP Securities Cannabis Conference, April 16, 2019 (also in Toronto)

MediPharm Labs takes part in presentations and discussions like such all through the year.

After 7 years at Aird & Berlis LLP, Daniel Overall is joining the MediPharm Labs. He was then appointed as an associate in the firm’s Capital Markets Group, a founding member of the firm’s Cannabis Group and the Director of its Startup Team. He also regularly counseled cannabis and non-cannabis startups. Daniel had a significant role in counseling the MediPharm Labs Inc. on their reverse take-over of POCML 4 Inc. (and TSX-V listing) and a private placement of $22.3 million. He has a Juris Doctor from the University of Toronto’s Faculty of Law and a Bachelor of Commerce from the University of Alberta.

The MediPharm Labs (founded in 2015) has the characteristic of being the very first company in Canada which managed to become a licensed manufacturer of cannabis oil production without receiving a cannabis cultivation license first. This undivided focus on cannabis concentrates from the cGMP (current Good Manufacturing Practices) and the critical environment laboratories, allow MediPharm Labs to produce sterilized, pharmaceutical-level cannabis oil and concentrates. MediPharm Labs has invested in a specialist, research-oriented team, the latest technology, and special facilities to deliver clean and safe cannabis goods to consumers. The Labs’ private label program is a high-profit business, whereby it acquires the dry cannabis flower produces proprietary cannabis oil concentrate products for resale internationally through a private label.

Through the MediPharm Labs Australia Pty. Ltd. (it’s subsidiary), MediPharm Labs has also concluded its application with the federal Office of Drug Control to mine and trade in medical cannabis goods in Australia.